Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids

NCT07508787 is registered in ClinicalTrials.gov with Nefro Avillion Clinical Development, LLC as lead sponsor.

NCT NCT07508787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07508787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids
Lead sponsor
Nefro Avillion Clinical Development, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
June 29, 2026
Completion date
March 28, 2028
Enrollment
120 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

renal transplant failure and rejection